Prostate cancer doesn’t have a single cause. It develops from a combination of genetic predisposition, hormonal activity, aging-related cellular changes, and lifestyle factors that together push normal prostate cells toward uncontrolled growth. About 12.9% of men will be diagnosed with prostate cancer during their lifetime, making it one of the most common cancers in men, with roughly 120 new cases per 100,000 men each year in the United States.
How Age Rewires Prostate Cells
Age is the single strongest risk factor for prostate cancer, and the reason goes deeper than “cells have more time to go wrong.” As the prostate ages, it undergoes chemical changes to its DNA that don’t alter the genetic code itself but change which genes get switched on or off. These are called epigenetic changes, and they accumulate steadily over decades.
One key pattern is that protective genes gradually get silenced. In aging prostate tissue, the control switches (called promoters) of several tumor-suppressing genes gain chemical tags that shut them down. At the same time, the overall DNA loses chemical tags that normally keep it stable, creating a more chaotic cellular environment. Researchers have measured this directly: the amount of a stabilizing chemical marker in prostate DNA drops progressively from normal tissue, to enlarged prostate tissue, to metastatic cancer. This loss of stability has been detected even in precancerous prostate tissue, suggesting it happens before a tumor forms rather than because of one.
Another age-related change involves a gene that controls a growth factor called IGF2. Normally, only one copy of this gene is active. With aging, both copies switch on in prostate tissue, effectively doubling the growth signal. This same pattern shows up in prostate cancer cells, connecting the dots between normal aging and tumor development.
The Role of Hormones
Testosterone and its more potent form, dihydrotestosterone (DHT), are the primary fuel for prostate cell growth, both normal and cancerous. These hormones enter prostate cells and bind to a receptor that then travels into the cell’s nucleus. Once there, it activates genes that tell the cell to grow, divide, and resist programmed death. In healthy tissue, this process is tightly regulated. In cancer, the system runs unchecked.
Specifically, hormones push prostate cells through critical growth checkpoints while simultaneously turning up the activity of proteins that prevent cell death. The result is cells that multiply faster and survive longer than they should. This hormonal dependence is so central to prostate cancer that one of the most common somatic alterations found in prostate tumors, the TMPRSS2:ERG gene fusion, works precisely by hijacking this hormone-driven machinery. This fusion places a cancer-promoting gene under the control of an androgen-regulated gene, fundamentally rewiring the cell’s behavior. It occurs early in tumor development and is considered a distinct cancer subtype that may be partly influenced by modifiable hormonal factors.
Inherited Genetic Mutations
Some men are born with gene mutations that significantly raise their prostate cancer risk. The most well-established inherited mutations involve three genes: BRCA2, BRCA1, and HOXB13.
- BRCA2 carriers face roughly 4 to 5 times the risk of prostate cancer compared to the general population. This is the same gene linked to breast and ovarian cancer in women.
- BRCA1 carriers have about 1.6 times the normal risk, a meaningful but more modest increase.
- HOXB13 was the first gene directly linked to hereditary prostate cancer. A specific variant of this gene raises risk 3 to 5-fold overall, and up to 10-fold for early-onset disease. Men carrying this variant have approximately a 60% lifetime chance of developing prostate cancer by age 80.
Current guidelines recommend genetic testing for men with strong family histories, looking at these genes along with several others involved in DNA repair. If you have a father or brother diagnosed with prostate cancer, especially before age 60, your own risk is elevated whether or not a specific mutation is identified.
Race and Prostate Cancer Disparities
Black men develop prostate cancer at significantly higher rates than white men and are more likely to be diagnosed with aggressive disease. The reasons are both biological and systemic. On the biological side, Black men tend to have higher baseline PSA levels (a marker of prostate activity) and carry genetic variants on chromosome 8q24 that are consistently linked to earlier cancer development, higher tumor grades, and greater risk of the cancer spreading.
But biology only tells part of the story. Black men report worse communication with doctors about screening, with only 60% describing good physician-patient communication compared to 71% of white men. Nearly half of Black men in one study reported being uneducated about screening options. Financial barriers compound the problem: 30.5% of Black cancer survivors reported financial hardship from cancer-related debt, compared to 18.5% of white survivors. Specialized cancer centers also tend to be located away from areas with large Black populations, creating geographic barriers to the best available care. These systemic factors mean that cancers that might have been caught early are instead diagnosed at later, harder-to-treat stages.
Chronic Inflammation as a Driver
Long-term inflammation inside the prostate creates conditions that favor cancer development. When prostate tissue is chronically inflamed, whether from infections, diet, or other triggers, the cells in the surrounding glands begin to look abnormal. They proliferate faster despite appearing shrunken, a condition called proliferative inflammatory atrophy, or PIA. These rapidly dividing, stressed cells are considered potential precursor lesions for prostate cancer.
Researchers have identified cases where bacterial infection-associated PIA lesions were caught in the process of transitioning into early invasive cancer, providing direct visual evidence of this inflammation-to-cancer pathway. This is why conditions that cause persistent prostate inflammation, including recurrent infections and prostatitis, are considered relevant to long-term cancer risk.
Obesity and Metabolic Health
Obesity doesn’t just raise prostate cancer risk in general; it specifically increases the risk of aggressive prostate cancer. The connection runs through several biological pathways. Excess body fat drives insulin resistance, which elevates levels of insulin and insulin-like growth factors. These act as potent growth signals for prostate cells. Obesity also triggers chronic low-grade inflammation throughout the body and disrupts normal sex hormone levels, both of which feed into cancer-promoting conditions.
Metabolic syndrome, the cluster of high blood sugar, excess abdominal fat, abnormal cholesterol, and high blood pressure, ties together many of these mechanisms. The abnormal insulin signaling, inflammatory changes, disrupted hormone levels, and impaired glucose metabolism associated with metabolic syndrome all independently contribute to a cellular environment where prostate cancer can take hold and progress.
Diet and Nutritional Factors
The relationship between specific foods and prostate cancer is less clear-cut than many people assume. Lycopene, the compound that gives tomatoes their red color, has been widely promoted as protective, but a systematic review of randomized controlled trials found insufficient evidence to either support or refute its use for prostate cancer prevention. Selenium, a mineral with antioxidant properties, showed a modest reduction in prostate cancer risk in pooled analyses, but the evidence base remains limited.
General dietary guidelines emphasize eating five or more servings of vegetables and fruits daily as potentially protective, though the specific mechanisms and degree of benefit are still under investigation. What the evidence supports more strongly is the indirect dietary connection: diets that promote obesity and metabolic dysfunction create the hormonal and inflammatory conditions described above, which do have well-established links to aggressive prostate cancer.
Environmental and Occupational Exposures
Certain workplace chemicals have been investigated as possible contributors to prostate cancer, though the evidence is less definitive than for genetic or hormonal factors. Exposure to toxic metals (including cadmium, chromium, lead, and nickel), non-mineral lubricant oils, pesticides, diesel fumes, and other combustion byproducts has been studied in industrial and agricultural workers. Research from a case-control study in Western Australia found non-statistically significant increases in prostate cancer risk associated with toxic metal exposure and industrial oils, suggesting a possible link that hasn’t been firmly established.
The challenge with occupational studies is accounting for the long delay between exposure and cancer development. Researchers typically exclude exposures from the five years immediately before diagnosis to account for latency, but prostate cancer can take decades to develop, making it difficult to pin down exactly which exposures matter most.
How These Factors Work Together
Prostate cancer rarely results from any single cause. A more realistic picture is one where aging gradually weakens the molecular safeguards in prostate cells, inherited mutations remove additional layers of protection, hormones provide a constant growth stimulus, and lifestyle factors like obesity or chronic inflammation tip the balance toward uncontrolled cell division. Some of these factors, like your genes and age, are fixed. Others, like body weight, metabolic health, and inflammatory conditions, offer at least some opportunity for risk reduction.